

Dear Editor,

Thank you for considering the manuscript entitled “Multiple Myeloma Complicating Guillain-Barre Syndrome After Bortezomib Therapy: A Case Report” (48078) . We really appreciate all the comments from reviewers. We have substantially revised the manuscript and a point-by-point response was enclosed. We would like to re-submit the revised manuscript to the *World Journal of Clinical Cases*, and hope it is acceptable for publication in the journal. Please do not hesitate to contact us for any question or concern.

We look forward to your final decision.

Sincerely yours

YuLing,Xu

**Responses to reviewer :**

1. I would suggest rephrasing the following sentence to clarify its meaning: “Nearly half the patients treated with bortezomib had PN of varying degrees, and 30% had moderate to severe PN. The symptoms did not improve after treatment. Therefore...”. No improvement was seen in all patients? Or those with “moderate to severe PN”?

Respond: Thank you. The sentence means that no improvement was seen in some patients. We have revised the sentence in the article.

2. BIPN is defined above and re-defined later (just before case presentation). I believe a few sub-headings could be merged into a single section, namely: Chief complaints, History of present illness, History of past illness, Personal and family history and Physical examination upon admission.

Respond: We have corrected the words in the article.

3. Acute inflammatory demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN) are defined in discussion but the acronyms are not further used.

Respond: We have deleted the words in the article. No acronyms are required.

4. Please clarify the last sentence used in discussion: "The patient was excluded from venetoclax group but did not report the patient[11]."

Respond: We have corrected the sentence in the article.